Clinical features of docetaxel chemotherapy-related lymphedema

Lymphatic Research and Biology

Volumn 12, Issue 3, 2014, Pages 197-202

  Park, Sae In ^a   Jeon, Woo Hyun ^a   Jeung, Ho Joong ^a   Kim, Ghi Chan ^a   Kim, Dong Kyu ^a   Sim, Young Joo ^a  

^a Kosin University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DECONGESTIVE AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FUROSEMIDE; PROTEIN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ARM; ARM WEAKNESS; ARTICLE; BANDAGING TECHNIQUE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; ELECTROLYTE BLOOD LEVEL; FEMALE; HUMAN; LEG; LEG WEAKNESS; LYMPHEDEMA; LYMPHOSCINTIGRAPHY; MASTECTOMY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; PERIPHERAL EDEMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; BREAST NEOPLASMS; CHEMICALLY INDUCED; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHEDEMA; MIDDLE AGED; TAXOIDS;

EID: 84907220689     PISSN: 15396851     EISSN: 15578585     Source Type: Journal    
DOI: 10.1089/lrb.2013.0037     Document Type: Article

References (14)

1. Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C. The risk of developing arm lymphedema among breast cancer survivors: A meta-Analysis of treatment factors. Ann Surg Oncol 2009;16:1959-1972.
2. Cueni LN, Detmar M. The lymphatic system in health and disease. Lymphat Res Biol 2008;6:109-122.
3. Kocak Z, Overgaard J. Risk factors of arm lymphedema in breast cancer patients. Acta Oncol 2000;39:389-392.
4. Ugur S, Arici C, Yaprak M, Mesci A, Arici GA, Dolay K, Ozmen V. Risk factors of breast cancer-related lymphedema. Lymphat Res Biol 2013;11:72-75.
5. Jeon YS, Kang SH, Lee SJ. Docetaxel-induced severe fluid retention in a breast cancer patient: A case report. J Breast Cancer 2010;13:231-235.
6. Markman M. Managing taxane toxicities. Support Care Cancer 2003;11:144-147.
7. Béhar A, Pujade-Lauraine E, Maurel A, et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 1997;43: 653-658.
8. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49-59.
9. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994;12:1458-1467.
10. Joachim E. Lymphedema Management. New York; Thieme. 2004; pp. 41-44.
11. Dominick SA, Madlensky L, Natarajan L, Pierce JP. Risk factors associated with breast cancer-related lymphedema in the WHEL Study. J Cancer Surviv 2013;7:115-123.
12. Norman SA, Localio AR, Kallan MJ, et al. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev 2010;19:2734-2746.
13. Massacesi C, Marcucci F, Rocchi MB, Mazzanti P, Pilone A, Bon-signori M. Factors predicting docetaxel-related toxicity: Experience at a single institution. J Chemother 2004;16:86-93.
14. Pronk LC, van Putten WL, van Beurden V, de Boer-Dennert M, Stoter G, Verweij J. The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxelinduced fluid retention: Results of a comparative study. Cancer Chemother Pharmacol 1999;43:173-177.